As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data showing its ...
Wave Life Sciences Ltd. plans to file with the U.S. FDA for accelerated approval of WVE-N531, an exon skipping ...
Clinical Trials Arena on MSN14h
Duchenne muscular dystrophy: Five trials to watchAmid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five DMD trials to keep an eye on in 2025.
Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback